Jan FMeilof, neurologist, Dpt Neurology, Martini Hospital, PO Box 30033, 9700RM Groningen, The Netherlandsmeilofjf@mzh.nl
Submitted August 26, 2015
I read with interest the article by Constantinescu et al. [1] I feel that the Classification of Evidence is somewhat overrated for this trial. Treating 21 patients over 20 weeks is hardly class I evidence for good tolerability. For such a conclusion, the numbers of patients treated must be at least a 10-fold higher and the treatment period significantly longer.
1. Constantinescu CS, Asher A, Fryze W, et al. Randomized phase 1b trial of MOR103, a human antibody to GM-CSF, in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 2015;2:e117.
For disclosures, please contact the editorial office at nnnjournal@neurology.org.
I read with interest the article by Constantinescu et al. [1] I feel that the Classification of Evidence is somewhat overrated for this trial. Treating 21 patients over 20 weeks is hardly class I evidence for good tolerability. For such a conclusion, the numbers of patients treated must be at least a 10-fold higher and the treatment period significantly longer.
1. Constantinescu CS, Asher A, Fryze W, et al. Randomized phase 1b trial of MOR103, a human antibody to GM-CSF, in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 2015;2:e117.
For disclosures, please contact the editorial office at nnnjournal@neurology.org.